Table 3.

Clinical outcomes

	No. of patients, n (%)	Clinical cure, n (%)
Clinical success ETE	134	118 (88.1)
Clinical success PTE	130	104 (80.0)
Subgroups evaluated at ETE
Four-dose regimen	118 (88.1)	107 (90.7)
Five-dose regimen	16 (11.9)	11 (68.8)
MRI-proven infection	128 (95.5)	113 (90.4)
Diabetes	51 (38.1)	43 (84.3)
Prosthetic device	24 (17.9)	20 (88.3)
Heart failure	25 (18.7)	21 (84)
Previous antibiotic therapy	18 (13.4)	14 (77.8)
Malignancy on immunosuppression	12 (9)	11 (91.7)

ETE end of the last dose, MRI magnetic resonance imaging, PTE post-treatment